US EditionBioVaxys and Sona partner to develop cancer therapeutics
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
BioVaxys Technology Corp. And Sona Nanotech Inc. Enter Research Collaboration - Canadian Manufacturing
VANCOUVER and HALIFAX — BioVaxys Technology Corp. and Sona Nanotech Inc. announce that they have entered into a Research Agreement to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX Immune Educating Platform in combination with Sona’s Targeted Hyperthermia Therapy, a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared l…
Targeted Hyperthermia Therapy: Sona's Cancer Treatment
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX™ Immune Educating Platform (“DPX”) in combination with Sona’s Targeted Hyperthermia Therapy™ (“THT”), a photothermal cancer therapy that uses highly t…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
